Affiliation:
1. Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA.
Abstract
Nelfinavir mesylate (formerly AG1343) is a potent and selective, nonpeptidic inhibitor of human immunodeficiency virus type 1 (HIV-1) protease that was discovered by protein structure-based design methodologies. We evaluated the antiviral and cytotoxic effects of two-drug combinations of nelfinavir with the clinically approved antiretroviral therapeutics zidovudine (ZDV), lamivudine (3TC), dideoxycytidine (ddC; zalcitabine), stavudine (d4T), didanosine (ddI), indinavir, saquinavir, and ritonavir and a three-drug combination of nelfinavir with ZDV and 3TC against an acute HIV-1 strain RF infection of CEM-SS cells in vitro. Quantitative assessment of drug interaction was evaluated by a universal response surface approach (W. R. Greco, G. Bravo, and J. C. Parsons, Pharm. Rev. 47:331-385, 1995) and by the method of M. N. Prichard and C. Shipman (Antiviral Res. 14:181-206, 1990). Both analytical methods yielded similar results and showed that the two-drug combinations of nelfinavir with the reverse transcriptase inhibitors ZDV, 3TC, ddI, d4T, and ddC and the three-drug combination with ZDV and 3TC resulted in additive to statistically significant synergistic interactions. In a similar manner, the combination of nelfinavir with the three protease inhibitors resulted in additive (ritonavir and saquinavir) to slightly antagonistic (indinavir) interactions. In all combinations, minimal cellular cytotoxicity was observed with any drug alone and in combination. These results suggest that administration of combinations of the appropriate doses of nelfinavir with other currently approved antiretroviral therapeutic agents in vivo may result in enhanced antiviral activity with no associated increase in cellular cytotoxicity.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference34 articles.
1. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay;Alley M. C.;Cancer Res.,1988
2. Review of the application of response surface methodology in the combination therapy of cancer;Carter W. H.;Cancer Treatment Rep.,1986
3. Cohen C. E. Sun W. Cameron D. McMahon C. Farthing D. Poretz M. Markowitz S. Follansbee J. Mellors D. Ho A. Hsu R. Maki M. Salgo and J. Leonard. 1996. Ritonavir-saquinavir combination treatment in HIV-infected patients abstr. LB7b p. 8. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy Addendum. American Society for Microbiology Washington D.C.
4. Conant M. M. Markowitz A. Hurley D. Ho J. Peterkin and S. Chapman. 1996. A randomized phase II dose range-finding study of the HIV protease inhibitor VIRACEPT~ as monotherapy in HIV positive patients abstr. Tu.B.2129. In Abstracts of the XI International Conference on AIDS.
5. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors;Condra J. H.;Nature,1995
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献